<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: To assess both acid <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux</z:e> (GOR) suppression in patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> on <z:chebi fb="0" ids="49200">proton-pump inhibitors</z:chebi> (<z:chebi fb="4" ids="53266">PPI</z:chebi>) and the predictive value of symptoms </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN A prospective study of patients with Barrett's epithelium (&gt; 3 cm, containing specialized <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath>) </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: Forty-five patients with Barrett's epithelium were recruited </plain></SENT>
<SENT sid="3" pm="."><plain>Therapy was adjusted to <z:chebi fb="14" ids="7772">omeprazole</z:chebi> 20 mg twice daily </plain></SENT>
<SENT sid="4" pm="."><plain>Oesophageal manometry and 24 h pH studies were performed on treatment </plain></SENT>
<SENT sid="5" pm="."><plain>Heartburn score was calculated before and after <z:chebi fb="4" ids="53266">PPI</z:chebi> dose adjustment </plain></SENT>
<SENT sid="6" pm="."><plain>In patients with persisting <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e>, <z:chebi fb="14" ids="7772">omeprazole</z:chebi> dose was increased to 20 mg three times daily and pH studies repeated </plain></SENT>
<SENT sid="7" pm="."><plain>Adequacy of GOR suppression, assessed by pH monitoring, was related to heartburn score (0-3) </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Twenty of the 45 patients were symptomatic (mean score 1.9) on pre-study treatment (mainly <z:chebi fb="14" ids="7772">omeprazole</z:chebi> &lt; 20 mg once daily); on <z:chebi fb="14" ids="7772">omeprazole</z:chebi> 20 mg twice daily, only six patients remained symptomatic (mean score 1.6) </plain></SENT>
<SENT sid="9" pm="."><plain>Ten patients (22%) had persisting GOR on <z:chebi fb="14" ids="7772">omeprazole</z:chebi> 20 mg twice daily (median % total time with pH &lt; 4 was 8%) </plain></SENT>
<SENT sid="10" pm="."><plain>Abnormal nocturnal reflux was found in nine and abnormal daytime reflux in only four patients </plain></SENT>
<SENT sid="11" pm="."><plain>Heartburn persisted in three of these 10 patients (30%) </plain></SENT>
<SENT sid="12" pm="."><plain>Those remaining symptomatic had more daytime <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> than the asymptomatic patients with persistent reflux (median percentage daytime at pH &lt; 4 was 13.6% vs 0.6%, respectively; P &lt; 0.01) </plain></SENT>
<SENT sid="13" pm="."><plain>By increasing the <z:chebi fb="14" ids="7772">omeprazole</z:chebi> dose to 20 mg three times daily, only three of the 10 had persistent <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: Persistent <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> on <z:chebi fb="4" ids="53266">PPI</z:chebi> therapy is common in patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="15" pm="."><plain>Although nocturnal <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> is the most common finding, symptoms tended to occur in those with abnormal daytime reflux </plain></SENT>
<SENT sid="16" pm="."><plain>Symptom resolution does not guarantee <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> control </plain></SENT>
</text></document>